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As a new promoter of EMT, LOXL2 is found in several epithelial cancer cell lines. We found that LOXL2 was highly expressed in cholangiocarcinoma (CC) tissues and was associated with CC invasion and metastasis through EMT. Accordingly, we provided evidence for the hypothesis that HCVc can promote EMT in CC cell through LOXL2. We estimate that the mechanism may have two aspects: on the one hand, HCVc may interact with LOXL2, making its expression atopic and increasing its activity; on the other hand, HCVc may promote LOXL2 transcription.
Many results support LOXL2 as a new poor prognosis marker or novel therapeutic target in squamous cell carcinomas and gastric cancer.
2,3 LOXL2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells. 4 Furthermore, LOXL2 activity might be a crucial modulator of Snai1, providing an additional control mechanism of EMT and tumor progression. To better understand the participation of Snai1 and LOXL2 molecules, Peinado et al. have performed in-depth in vitro and in vivo studies of HaCa4 cells with silenced expression of Snai1 or LOXL2. These results suggest that LOXL2 influences the Snai1-dependent invasion properties and, perhaps, the Snai1-prosurvival action, but, in addition, LOXL2 has specific functions in the negative control of the epidermal differentiation program, apparently through the direct or indirect regulation of Snai1-independent target genes.
Subsequent mechanistic studies showed that LOXL2 could activate both the Snai1/E-cadherin and Src kinase/ focal adhesion kinase (Src/FAK) pathways. However, secreted LOXL2 induced gastric tumor cell invasion and metastasis exclusively via the Src/FAK pathway but not the Snai1/E-cadherin pathway. 
